denotes an abstract that is clinically relevant.
denotes that this is a recommended PHD Trainee Session.
denotes that this is a ticketed session.Sponsor: Education
Program: Spotlight Sessions
Hematology Disease Topics & Pathways:
Sickle Cell Disease, Hemoglobinopathies, Diversity, Equity, and Inclusion (DEI), Diseases, Gene Therapy, Treatment Considerations, Biological therapies, Transplantation (Allogeneic and Autologous)
Hematology Disease Topics & Pathways:
Sickle Cell Disease, Hemoglobinopathies, Diversity, Equity, and Inclusion (DEI), Diseases, Gene Therapy, Treatment Considerations, Biological therapies, Transplantation (Allogeneic and Autologous)
Sunday, December 8, 2024: 4:30 PM-5:45 PM
Room 30
(San Diego Convention Center)
Chair:
Payal Desai, MD, Atrium Health
Disclosures:
No relevant conflicts of interest to declare.
Despite substantial improvements in care, individuals with sickle cell disease continue to experience substantial morbidity and a shortened life expectancy. With recent advances in the development of curative therapies, including allogeneic stem cell transplantation and gene therapy, it is important to identify barriers to accessing these treatments and adequately define suitable candidates for curative therapies.
In this session, Dr. Santosh Saraf will review the current guidelines for curative therapies, discuss the potential benefits and risks of the different curative therapies, and provide insight on when to refer patients for curative therapy.
In the second presentation, Dr. Payal Desai will discuss the various barriers to accessing curative therapies as well as the need for development of an integrated care approach.
See more of: Spotlight Sessions